IGLV2-8

Across TCGA pan-cancer cohorts, IGLV2-8 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of IGLV2-8’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGLV2-8 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGLV2-8 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where IGLV2-8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV2-8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−1.034	<.001	12	view →
COAD	Female	II,III,IV	−0.905	<.001	10	view →
LUAD	Female	All	−0.724	<.001	8	view →
PDAC	Female	All	+1.318	<.001	6	view →
LSCC	Male	All	−0.548	<.001	5	view →
OV	All	All	−0.973	.024	2	view →
CCRCC	All	All	+0.305	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

IGLV2-8–HNSC

Open the HNSC breakdown →